The battle against multiple myeloma, a formidable blood cancer, has received a significant boost thanks to a groundbreaking discovery by researchers at Adelaide University and SA Pathology. This team of scientists has identified a protein, Desmoglein-2 (DSG2), that could revolutionize the way we approach this disease. By pinpointing patients with aggressive forms of multiple myeloma before treatment begins, this discovery paves the way for more personalized care and improved outcomes.
A Protein Predictor
The study, published in the British Journal of Haematology, analyzed clinical and genomic data from 678 individuals newly diagnosed with multiple myeloma. Researchers found that those with elevated levels of DSG2 had significantly poorer survival rates compared to patients with lower DSG2 levels. This finding held true even after accounting for various factors, including age, disease stage, treatment type, and stem cell transplantation.
Lead author Professor Claudine Bonder emphasizes the significance of this discovery, stating, "While genomic testing has improved our ability to identify high-risk disease, some patients who appear to have standard-risk myeloma still experience rapid progression and poor survival. Our findings show that high DSG2 levels can identify patients with a particularly aggressive type of multiple myeloma that may not be captured by existing risk-stratification approaches."
Personalized Treatment
The potential impact of this discovery on personalized treatment is immense. Current risk assessments heavily rely on genomic testing, but DSG2 testing could become an additional tool to help clinicians identify high-risk patients earlier and tailor treatment plans from the outset. Co-lead author Dr. Barbara McClure highlights the importance of early identification, stating, "Rapidly identifying patients who are likely to have more aggressive forms of the disease is critical because it can influence treatment decisions from the very beginning."
Opening New Doors
The research team believes that this discovery could also open new avenues for future therapies. Further studies are planned to validate the findings and explore whether DSG2 itself could become a target for precision medicine treatments aimed at improving outcomes for people living with high-risk multiple myeloma.
If successful, this research could help clinicians better match treatments to individual patients, offering a more personalized approach to tackling one of the world's most common blood cancers. This breakthrough not only brings hope to patients but also underscores the importance of continued scientific exploration in the fight against cancer.
